Literature DB >> 15626914

Mucinous tumors of the ovary: a review.

William R Hart1.   

Abstract

Mucinous ovarian tumors are among the most difficult ovarian neoplasms for surgical pathologists to interpret. Approximately 20% of primary ovarian mucinous tumors are borderline tumors, noninvasive (intraglandular; intraepithelial) carcinomas, or invasive carcinomas; the remainder are cystadenomas. The borderline tumors may be of intestinal type or mullerian (endocervical-like) type. The intestinal-type tumors are by far the most common. Their frequently heterogeneous composition with coexisting elements of cystadenoma, stromal microinvasion, noninvasive carcinoma, and invasive carcinoma requires careful gross examination and extensive sampling of the tumors. The inherent glandular complexity of proliferating mucinous tumors complicates recognition of stromal invasion. Some mucinous carcinomas with expansile (confluent) invasion may be very difficult to discriminate from extensive noninvasive carcinoma. Interobserver reproducibility probably requires use of an arbitrary minimum size criterion for the diagnosis of expansile invasion. Primary invasive carcinomas with an infiltrative growth pattern are less common. Rarely, distinct mural nodules of reactive or neoplastic type are found in the cystic wall of a mucinous tumor. Pseudomyxoma peritonei almost never results from a ruptured primary ovarian mucinous neoplasm, but often produces secondary borderline-like ovarian tumors with prominent pseudomyxoma ovarii. Prognosis of mucinous tumors is highly dependent on stage and histologic composition. Borderline tumors, noninvasive carcinomas, microinvasive tumors, and invasive carcinomas with an expansile growth pattern are generally stage I and have an excellent prognosis with only occasional examples of metastatic spread. Invasive carcinomas with an infiltrative growth pattern are more aggressive, accounting for almost all high-stage mucinous tumors, and are responsible for most deaths caused by tumor. A high index of suspicion that a mucinous tumor is actually a metastasis from another organ is required by pathologists and gynecologists to prevent misdiagnosis of a metastatic neoplasm as a primary ovarian tumor. Secondary mucinous tumors are significantly more often bilateral, <10 cm in maximal dimension, and of high stage. Numerous immunohistochemical stains proposed to aid in the differential diagnosis of primary vs. secondary mucinous tumors also are reviewed.

Entities:  

Mesh:

Year:  2005        PMID: 15626914

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  53 in total

Review 1.  Spectrum of mucin-producing neoplastic conditions of the abdomen and pelvis: cross-sectional imaging evaluation.

Authors:  Nam Kyung Lee; Suk Kim; Hyun Sung Kim; Tae Yong Jeon; Gwang Ha Kim; Dong Uk Kim; Do Youn Park; Tae Un Kim; Dae Hwan Kang
Journal:  World J Gastroenterol       Date:  2011-11-21       Impact factor: 5.742

Review 2.  Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society of Radiologists in Ultrasound Consensus Conference Statement.

Authors:  Deborah Levine; Douglas L Brown; Rochelle F Andreotti; Beryl Benacerraf; Carol B Benson; Wendy R Brewster; Beverly Coleman; Paul Depriest; Peter M Doubilet; Steven R Goldstein; Ulrike M Hamper; Jonathan L Hecht; Mindy Horrow; Hye-Chun Hur; Mary Marnach; Maitray D Patel; Lawrence D Platt; Elizabeth Puscheck; Rebecca Smith-Bindman
Journal:  Radiology       Date:  2010-05-26       Impact factor: 11.105

3.  Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study.

Authors:  Richard J Zaino; Mark F Brady; Subodh M Lele; Helen Michael; Benjamin Greer; Michael A Bookman
Journal:  Cancer       Date:  2010-09-22       Impact factor: 6.860

Review 4.  Unmasking the complexities of mucinous ovarian carcinoma.

Authors:  Michael Frumovitz; Kathleen M Schmeler; Anais Malpica; Anil K Sood; David M Gershenson
Journal:  Gynecol Oncol       Date:  2010-03-23       Impact factor: 5.482

5.  Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.

Authors:  Kevin M Elias; S Intidhar Labidi-Galy; Allison F Vitonis; Jason L Hornick; Leona A Doyle; Michelle S Hirsch; Daniel W Cramer; Ronny Drapkin
Journal:  Gynecol Oncol       Date:  2013-12-14       Impact factor: 5.482

Review 6.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

7.  Gemcitabine-based regimen for primary ovarian angiosarcoma with MYC amplification.

Authors:  I Yonezawa; M Waki; Y Tamura; R Onoda; M Narushima; T Ishizuka; S Tajima
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

Review 8.  Mucinous cystic neoplasms.

Authors:  Carlos Fernández-del Castillo
Journal:  J Gastrointest Surg       Date:  2007-10-23       Impact factor: 3.452

9.  Hereditary breast and ovarian cancer.

Authors:  Jacek Gronwald; Tomasz Byrski; Tomasz Huzarski; Oleg Oszurek; Anna Janicka; Jolanta Szymanska-Pasternak; Bohdan Górski; Janusz Menkiszak; Izabella Rzepka-Górska; Jan Lubinski
Journal:  Hered Cancer Clin Pract       Date:  2008-06-15       Impact factor: 2.857

Review 10.  [Mucinous ovarian neoplasms. Prognostically mostly excellent, infrequently a wolf in sheep's clothing].

Authors:  S Lax; A Staebler
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.